SEC Comment Letter 0000000000-23-012074 to Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc.
Date: Nov. 3, 2023 · CIK: 0001583771 · Accession: 0000000000-23-012074
AI Filing Summary & Sentiment
File numbers found in text: 333-275231
Letter
United States securities and exchange commission logo November 3, 2023 Robert Foster, Ph.D. Chief Executive Officer Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Re:Hepion Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed October 31, 2023 File No. 333-275231 Dear Robert Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey J. Fessler, Esq.
Show Raw Text
United States securities and exchange commission logo
November 3, 2023
Robert Foster, Ph.D.
Chief Executive Officer
Hepion Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
Re:Hepion Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed October 31, 2023
File No. 333-275231
Dear Robert Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey J. Fessler, Esq.